Beyond Cholesterol: How We Personalize Heart Risk and Treatment
Heart risk is rarely defined by one number alone. A standard cholesterol panel can be helpful, but it does not always tell you how much risk is actually building beneath the surface. That is part of what the new 2026 ACC/AHA dyslipidemia guideline makes clear: better prevention requires more than a routine lipid panel. It requires a more complete view of risk — one that may include ApoB, lipoprotein(a), coronary calcium scoring, and more personalized treatment decisions based on the full picture.
At Synergy, that is how we think about cardiovascular prevention. We do not treat cholesterol in isolation. We look at advanced lipids, inherited risk, metabolic health, lifestyle patterns, imaging, and other cardiovascular data to understand whether risk is theoretical, emerging, or already present.
Why imaging matters
One of the most important ideas in modern prevention is that lab work and imaging answer different questions. Labs help estimate risk. Imaging can show whether disease is already taking shape.
That distinction matters. A patient may have borderline numbers and still have meaningful plaque burden. Another may have concerning biomarkers but no measurable calcified plaque yet. This is why the new guideline gives coronary artery calcium, or CAC, a more explicit role in risk assessment. In appropriate adults, CAC can improve risk classification and help guide LDL-C and non-HDL-C goals, particularly when the treatment decision is not obvious from standard risk estimation alone.
For us, that is not a minor point. Imaging is not an afterthought. It is one of the central tools that helps personalize prevention. A cholesterol panel can suggest possibility. CAC helps show whether there is already objective evidence of plaque. In selected patients, going a step further with coronary CT angiography, or CCTA, can add even more clarity by showing plaque burden and anatomy in greater detail. At Synergy, we pair CCTA with Cleerly plaque analysis, an AI-enabled, FDA-cleared platform that helps identify, characterize, and quantify coronary plaque in a more advanced way than a standard read alone. Cleerly describes its platform as using FDA-cleared machine-learning algorithms to measure plaque, stenosis, and likely ischemia from CCTA studies, and Synergy’s own heart-health page describes Cleerly coronary analysis as a complete evaluation of plaque presence, amount, and type based on CCTA. Cleerly also maintains a national network of integrated imaging centers that can perform CCTA and send scans for analysis, which is why I would describe this as an advanced capability available at a limited number of integrated centers rather than claim exclusivity more narrowly.
In plain English: if you are trying to decide how aggressive prevention should be, seeing the arteries can matter.
Why treatment should be personalized
The updated guideline is more proactive, but it is not simplistic. It does not say that everyone needs the same treatment or that medication is the first answer in every case. It does, however, support earlier and more targeted intervention when the data justify it.
The guideline restores LDL-C and non-HDL-C treatment goals and recommends lower targets as risk increases. That reflects a broader shift toward reducing atherogenic exposure earlier and more intentionally over time.
That is where personalization matters.
Two patients with the same LDL-C may not need the same plan. One may do very well with lifestyle intensification and follow-up. Another may have elevated ApoB, high Lp(a), metabolic dysfunction, or evidence of plaque on imaging that pushes the conversation in a different direction. The purpose of a more advanced evaluation is not to overmedicalize prevention. It is to avoid undertreating risk that is already present.
Lifestyle still comes first — but not lifestyle alone at all costs
This is an important point, especially for patients who are wary of medication.
Lifestyle remains the foundation of prevention. Nutrition quality, exercise, body composition, blood pressure control, sleep, tobacco avoidance, and metabolic health all matter. The American Heart Association’s patient-facing summary of the guideline continues to emphasize healthy eating patterns, physical activity, weight management, and other core habits as the basis of cholesterol and heart-risk management.
At Synergy, we take that seriously. We are lifestyle-first in the sense that we want to understand how a patient eats, trains, sleeps, recovers, and lives before jumping to conclusions. But lifestyle-first does not mean lifestyle-only at all costs. When biomarkers and imaging show that risk is real, or when inherited risk is clearly part of the story, it is appropriate to have a frank discussion about whether medication should be part of the plan.
That discussion should be individualized. It should weigh the magnitude of benefit, the patient’s goals, the overall risk profile, and the likely trajectory over time. Some patients need reassurance. Some need closer monitoring. Some need a more aggressive plan. Good prevention is knowing the difference.
How we implement this at Synergy
Our approach is built around a simple question: what is the most accurate way to understand this patient’s cardiovascular risk, and what is the most reasonable way to lower it?
That usually starts with the basics — a standard lipid panel, blood pressure, body composition, personal and family history, and a close look at lifestyle patterns. From there, we often add advanced markers such as ApoB and Lp(a) to better define particle-related and inherited risk. The new guideline recommends measuring Lp(a) at least once in adulthood and supports ApoB testing to improve risk assessment and guide therapy, especially when triglycerides are elevated, diabetes is present, or residual risk may be underestimated by the standard lipid profile.
When risk remains uncertain — or when family history, advanced lipids, or other findings suggest the need for more clarity — imaging becomes central. CAC can help determine whether plaque is already present and how aggressive LDL lowering should be. In selected cases, CCTA can provide a more refined understanding of coronary plaque and anatomy. At Synergy, that includes Cleerly plaque analysis, which adds AI-enabled plaque characterization and quantification on top of the CCTA itself. That is especially useful when we want to move beyond abstract risk estimation and understand the biology more directly.
Once we have that picture, treatment becomes more precise. Some patients need tighter lifestyle structure and follow-up. Some need treatment escalation with statins or nonstatin therapies such as ezetimibe, bempedoic acid, or PCSK9-directed therapy, depending on their risk profile and treatment goals. The point is not to force everyone into the same algorithm. The point is to build a plan that matches the actual level of risk.
What this means for you
If there is one takeaway from this series, it is this: cardiovascular prevention is moving away from simplistic screening and toward more personalized risk assessment.
That is a good thing.
For patients, the better question is not just, “Is my cholesterol normal?” It is:
- Do I know my ApoB?
- Have I ever checked my Lp(a)?
- Would imaging help clarify my risk?
- Is my current plan actually matched to my biology?
The new guideline supports that broader, smarter conversation. At Synergy, that is the conversation we want patients to have — one grounded in better data, better interpretation, and more thoughtful prevention.
At Synergy, we welcome those questions. If you want a more personalized understanding of your heart risk — and a plan built around your actual data rather than generic averages — this is exactly the kind of care model we believe patients deserve.
Want a more personalized look at your cardiovascular risk?
Synergy combines advanced lipid testing, cardiovascular imaging, and physician-led interpretation to help you move beyond basic screening and toward a more precise prevention strategy. Explore our advanced heart screening options or schedule a consultation to start the conversation.